Literature DB >> 11070173

Partial impairment of cytokine responses in Tyk2-deficient mice.

M Karaghiosoff1, H Neubauer, C Lassnig, P Kovarik, H Schindler, H Pircher, B McCoy, C Bogdan, T Decker, G Brem, K Pfeffer, M Müller.   

Abstract

To assess the role of the Janus kinase (Jak) family member Tyk2, we have generated Tyk2-/- mice. In contrast to other Jaks, where inactivation leads to a complete loss of the respective cytokine receptor signal, Tyk2-/- mice display reduced responses to IFNalpha/beta and IL-12 and a selective deficiency in Stat3 activation in these pathways. Unexpectedly, IFNgamma signaling is also impaired in Tyk2-/- mice. Tyk2-/- macrophages fail to produce nitric oxide upon lipopolysaccharide induction. Tyk2-/- mice are unable to clear vaccinia virus and show a reduced T cell response after LCMV challenge. These data imply a selective contribution of Tyk2 to the signals triggered by various biological stimuli and cytokine receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070173     DOI: 10.1016/s1074-7613(00)00054-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  138 in total

Review 1.  Series introduction. JAK-STAT signaling in human disease.

Authors:  Christian W Schindler
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  IFNs and STATs in innate immunity to microorganisms.

Authors:  Thomas Decker; Silvia Stockinger; Marina Karaghiosoff; Mathias Müller; Pavel Kovarik
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons.

Authors:  Andreas Pilz; Katrin Ramsauer; Hamid Heidari; Michael Leitges; Pavel Kovarik; Thomas Decker
Journal:  EMBO Rep       Date:  2003-03-21       Impact factor: 8.807

Review 4.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 5.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

6.  JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age.

Authors:  Ming Xu; Tamara Tchkonia; Husheng Ding; Mikolaj Ogrodnik; Ellen R Lubbers; Tamar Pirtskhalava; Thomas A White; Kurt O Johnson; Michael B Stout; Vojtech Mezera; Nino Giorgadze; Michael D Jensen; Nathan K LeBrasseur; James L Kirkland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 7.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  Regulation of TLR4-mediated signaling by IBP/Def6, a novel activator of Rho GTPases.

Authors:  Qinzhong Chen; Sanjay Gupta; Alessandra B Pernis
Journal:  J Leukoc Biol       Date:  2008-12-12       Impact factor: 4.962

9.  Expression of cytokine signal transduction components in the postnatal mouse retina.

Authors:  Kun Do Rhee; Xian-Jie Yang
Journal:  Mol Vis       Date:  2003-12-16       Impact factor: 2.367

10.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.